Core Viewpoint - The research led by J. Craig Venter demonstrates the revival of "dead cells" through whole genome transplantation, creating what are termed "zombie cells" [3][4]. Group 1: Research Methodology - The study involved the use of mitomycin C (MMC) to inactivate the genome of Mycoplasma capricolum, rendering it "dead" before transplanting a synthetic genome from Mycoplasma mycoides [4][7]. - This approach eliminates the reliance on antibiotic resistance markers, which previously led to false positives due to homologous recombination in recipient cells [4][10]. - The new method allows for the transplantation of synthetic genomes into dead cells while maintaining their transcription and translation systems, thus enabling the revival of cellular functions [7][8]. Group 2: Efficiency and Breakthroughs - The new technique significantly enhances the efficiency of whole genome transplantation, achieving a success rate of one viable transplant cell from every 288 recipient cells, compared to the traditional method requiring 150 million cells for one successful transplant [9]. - This research marks the first instance of assembling a living synthetic bacterial cell from non-living components, overcoming the major barrier of false positives in genome transplantation [10]. - The findings suggest that any cell with a complete transcription and translation system could theoretically serve as a recipient for whole genome transplantation, paving the way for engineered cells with specific functions for applications in drug production, gene therapy, environmental remediation, and biofuel production [10].

Core Viewpoint - The article discusses a groundbreaking study on mitochondrial transplantation, which presents a new therapeutic approach for mitochondrial diseases and neurodegenerative disorders such as Parkinson's disease, leveraging encapsulated mitochondria for effective treatment [4][6][10]. Group 1: Research Findings - The study developed a new technique for mitochondrial encapsulation, allowing for efficient in vivo transplantation of mitochondria, significantly improving symptoms in models of Parkinson's disease, Leigh syndrome, and mitochondrial DNA depletion syndrome [5][10]. - The research introduces the concept of "organelle therapy," providing a novel treatment strategy for mitochondrial genetic diseases and neurodegenerative disorders [6][10]. - The encapsulation method utilizes red blood cell membranes to create "mitochondrial capsules," which protect the mitochondria and enhance their delivery into recipient cells, achieving a transplantation efficiency of approximately 80% compared to less than 5% for bare mitochondria [7][10]. Group 2: Implications and Applications - Mitochondrial transplantation can repair mitochondrial defects in patient-derived cells and is effective in treating mitochondrial DNA depletion syndrome and Leigh syndrome [8][10]. - In mouse models of Parkinson's disease, mitochondrial transplantation effectively prevented neuronal death and restored normal mitochondrial function, significantly improving motor abilities [10][11]. - This organelle therapy approach offers a more precise strategy compared to traditional cell therapies, potentially benefiting a wide range of diseases associated with mitochondrial dysfunction, including neurodegenerative diseases and metabolic disorders [10][11].